RPG Life Sciences' FY25 PBT Up By 28%
By Ankur Chandra | Published at: Jun 3, 2025 10:24 AM IST
Mumbai | June 3, 2025: RPG Life Sciences Ltd (NSE: RPGLIFE, BSE: 532983) has announced its financial results for FY25. The reports showcase stellar financial performance for FY25, driven by margin expansion, strong cash generation, and sustained top-line growth across all business segments.
Financial Performance Highlights (FY25)
| Metric | FY25 | FY24 | YoY Growth |
|---|---|---|---|
| Revenue | ₹653.4 crore | ₹582.1 Cr | 12% |
| PBT (excl. exceptionals) | ₹150.3 crore | ₹117.8 Cr | 28% |
| EBITDA Margin | 26.4% | 23.3% | +310 bps |
| PAT Margin | 17.1% | 15.1% | +200 bps |
| EPS (excl. exceptionals) | ₹67.5 | ₹53.0 | 27% |
| Cash Reserves | ₹168.2 crore | ₹127.6 Cr | 32% |
Segment wise Revenue Composition
- Domestic Formulations (DF): 66% of revenue
- International Formulations (IF): 20%
- APIs: 14%
Strategic & Operational Highlights
- Brand Growth: Naprosyn crossed ₹76 crore in FY25 and is on track to become RPG’s first ₹100 crore brand.
- New Therapies: Forayed into Ortho and Critical Care. Rheumatology franchise now 14% of speciality sales.
- Capex: Invested ~₹140 crore since FY22 to modernise plants and R&D with EU, TGA, and PIC/S compliance.
- Cash Flow: FY25 generated a surplus of ₹267 crore, creating room for potential inorganic growth.
- Sustainability: Achieved a 41% reduction in carbon emissions and a 52% cut in hazardous waste.
Ratings & Balance Sheet Strength
Credit rating agency ICRA reaffirmed RPG Life Sciences’ long-term rating at A+ (Stable) and short-term at A1. For the rating, it cited the company’s robust capital structure, healthy cash flows, and a debt-free status as key strengths.
Strategic Outlook: 7 Growth Pillars
- Portfolio Expansion: Scaling immunosuppressant and MABs brands.
- API Business: Entering new geographies and customer segments.
- Digital Transformation: Enhancing efficiency across front and back-end.
- M&A Pipeline: Evaluating synergistic acquisition targets.
- New Launches: Targeting high-growth therapies and adjacencies.
- Capacity Upgrades: Boosting manufacturing productivity.
- Talent Investment: Focus on upskilling and strategic hires across functions.
Management Commentary
The company stated that it aims to maintain its focus on operational excellence, innovation in chronic therapies, and cash-backed growth strategies. RPG Life Sciences’ future is well-positioned as it looks to sustain its leadership in speciality pharmaceuticals.
Company Overview:
RPG Life Sciences Ltd. is an Indian pharmaceutical company with a presence in over 50 markets. It offers branded formulations, global generics, and APIs and employs over 1,300 people across three manufacturing sites.
Dividend History:
The company has maintained a steady record of dividend payments in prior years, typically distributing 40-50% of its net profits. However, it has announced no dividend in this update.
Stock Price Effect
Although the company has performed well, the shares opened 0.30% lower at ₹2,168.60, down by 6.60 points from the previous close. The stock has a P/E ratio of 30.34, compared to a median industry P/E ratio of 33.42.
REF:https://nsearchives.nseindia.com/corporate/RPGLIFE_02062025201700_Investor_Presentation_Cover_Letter__2_.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. Every effort is made to ensure the accuracy, relevance, and timeliness of the information provided. However, inadvertent errors or omissions may occasionally occur.
Should you have any concerns, queries, or wish to point out any discrepancies in our content, please write to us at content@hdfcsec.com. Your feedback is valuable and helps us maintain the highest standards of content integrity.
Please note that the information shared is intended solely for informational purposes and should not be construed as investment advice. Users are advised to consult their financial advisors before making any investment decisions.
